REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Seckl, M. Ghorani, E. Quartagno, M. Gilbert, D. C. O'Brien, M. E. R. Ottensmeier, C. H. H. Pizzo, E. Spicer, J. F. Williams, A.
Seckl, M.
Ghorani, E.
Quartagno, M.
Gilbert, D. C.
O'Brien, M. E. R.
Ottensmeier, C. H. H.
Pizzo, E.
Spicer, J. F.
Williams, A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Seckl M, Ghorani E, Quartagno M, Blackhall FH, Gilbert DC, O'Brien MER, et al. REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005494.